← Back to headlines
Alnylam Pharmaceuticals Reports $3 Billion 2025 Revenue Target
Alnylam Pharmaceuticals has reported a target of $3 billion in revenue for 2025, driven by a 151% surge in its TTR franchise.
20 Feb, 09:08 — 20 Feb, 09:08
ℹOnly 1 source covers this story
